Publication date: May 21, 2026
To develop machine-learning (ML) models during the COVID-19 pandemic and adjacent time periods to evaluate the impact of data drift on model performance. This prognostic study used population-level administrative health data to develop ML prediction models. Alberta, Canada during 2019-2023. All patients over 18 who received at least one opioid dispensation from a community pharmacy within the province of Alberta between 2019-2023. Each opioid dispensation served as the unit-of-analysis. Opioid-related outcomes were identified from linked health administrative datasets. Light Gradient Boosting-machine models were developed on pre-pandemic, pandemic and endemic data and temporally validated on 2023 data (pre-pandemic model was also validated on 2020-2021 data) to predict the risk of emergency department visit, hospitalisation or mortality within 30-days of an opioid dispensation. We described key feature distributions across the study time period and changes in model prediction performance on the validation sets using relevant metrics. Among 1. 2 million study participants representing over 13 million opioid dispensations, there were 59 809 (2. 1%), 134 402 (2. 4%) and 62 143 (2. 3%) events reported in the pre-pandemic (2019), pandemic (2020 and 2021) and endemic (2022) time periods, respectively (estimated 2023 validation set pre-test probability of 2. 8%). Notable differences in key features were observed in the 2020-2021 model relative to other years. In the 2023 validation set, discrimination performance was highest for the pre-pandemic and endemic models compared with the pandemic model (0. 81, 0. 83, 0. 74, respectively). A similar trend regarding changes from pre-test to post-test probabilities in higher categories of predicted risk (23%, 40%, 16%) was observed. 2020-2021 had the lowest discrimination performance (0. 71) and uninformative post-test probabilities (
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | MESH | emergency |
| drug | DRUGBANK | Flunarizine |
| disease | MESH | Opioid-Related Disorders |